Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POTE ankyrin domain family member C (POTEC)
- Target
- POTEC
- Molecular classification
- Ankyrin repeat-containing protein, Cancer/testis antigen, Cytoskeletal-associated protein, Other (not a canonical receptor or enzyme)
01
Overview
POTE ankyrin domain family member C (POTEC) is part of the primate-specific POTE gene family, characterized by N-terminal cysteine-rich regions, five to seven ankyrin repeats, coiled-coil domains for protein interaction, and association with the plasma membrane. POTEC is notably expressed in healthy prostate, ovary, and testis, and is upregulated in various cancers, making it a cancer/testis antigen. The POTE gene family has evolutionary significance, with members dispersed across several primate chromosomes and is considered potentially involved in cell membrane structure and apoptosis in cancer cells[1][7][8][10]. Currently, POTEC is not a classical drug target but is of rising interest as a biomarker and putative immunotherapy antigen.
- Other names
- POTE18POTE-18DKFZp686J0529CT104.6A26B2Cancer/testis antigen family 104, member 6ANKRD26-like family B member 2Prostate, ovary, testis-expressed protein on chromosome 18
02
Mechanism of action
Not applicable, as no drugs are known to target POTEC directly[10].
03
Biological functions
Protein-protein interactions (via ankyrin repeats)Cell membrane associationPossible involvement in apoptosis (pro-apoptotic role in cancer contexts)Potential modulation of the cytoskeleton
04
Disease associations
Cancer (upregulated in several cancers such as breast, lung, colon, ovary, and esophageal adenocarcinoma)Biomarker for cancer progression (as a cancer/testis antigen)
05
Safety considerations
Not applicable as there are no drugs targeting POTEC and it is not used therapeutically[10].More generally, targeting cancer/testis antigens might pose risk for autoimmunity in future therapies.
06
Biomarkers
POTEC itself is considered a potential biomarker for cancer diagnosis, monitoring, and prognosis due to its cancer/testis-specific expression
Beyond the preview
Go deeper on POTE ankyrin domain family member C (POTEC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POTE ankyrin domain family member C (POTEC).